Abstract: Ischemic stroke is a common and often devastating disease that primarily affects the elderly. Treatment currently consists predominantly of acute thrombolysis and/or thrombectomy to restore blood flow. This reperfusion therapy, however, is only accessible to a small fraction of stroke patients, and even among these patients, many still suffer life-long neurologic deficits. Thus, new stroke therapeutics are urgently needed to improve the quality of life for stroke patients.